8 things to consider when choosing genetic testing for your patient

1. Maximized diagnostic potential with the highest performing NGS platform

All our diagnostic tests, regardless of whether you are testing a Single Gene, a Panel or WES, are performed on a high performing platform enabling flexibility. Comprehensive, publicly-available analytic validation of our platform is available on our website.

2. Customizable NGS panels with easy expansion to WES

Customize your panel by adding or removing genes at no additional cost. Expand to Exome from any panel or single gene test. High resolution copy number variant (CNV) analysis is always included.

3. Exceptional WES performance, with coverage of 99.4% at Depth >20x

Mean sequencing coverage of 174x offers highly uniform sequencing depth across all protein-coding genes.

4. Comprehensive diagnostics including non-coding variants

Clinically relevant, deep intronic variants included.

5. Clear and meaningful clinical report

Our interpretation team goes the extra mile to provide comprehensive variant classification for your patient.

6. Fast, friendly and knowledgeable customer service

Specialized, regionally focused teams available to you when you need them.

7. Easy ordering experience

Ordering a test from us is quick and simple. You can order online using our secure portal, Nucleus, or send us a requisition form by mail. Log in to Nucleus at nucleus.blueprintgenetics.com.

Nucleus allows you to place orders, read and securely share results as well as connect with other clinicians based on matching rare variants.

8. High resolution NGS-based CNV detection included

CNVs are an important disease mechanism that should be evaluated in all patients with a suspected inherited disorder, even with a previously normal chromosomal microarray. We offer best-in-class sensitivity for detecting CNVs, with >92% sensitivity for single-exon level deletions and >99% sensitivity for 5 exon CNVs.

Subscribe to our newsletter

Improving quality: Blueprint Genetics updates panels and prepares for the launch of mitochondrial DNA testing later this year

Subscribe to our newsletter